BioSpace News Archive

Emulate, Inc., a leading provider of advanced in vitro models, today unveiled the Emulate Brain-Chip, which is designed for neuroscience researchers investigating neuroinflammatory disease and for drug developers seeking to improve drug discovery for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Cognoptix, a leading healthcare company for early-stage detection of Alzheimer’s disease (AD), announces its co-founder, Lee Goldstein, M.D., Ph.D. has joined Cognoptix’s Scientific Advisory Board, serving as Co-Chair, and the company’s Board of Directors.

Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the first granted patent for an important patent family (i.e., a set of patents filed in various countries to protect an invention) was received by the Company from the Australian Patent Office.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its QuickVue® SARS Antigen test,

Neuropathix, Inc. (OTCQB: NPTX), (the “Company” or “Neuropathix”), a socially responsible pain management life sciences company, announced today that it acquired neuroprotective and anticonvulsant small-molecule drug technology from Advanced Neural Dynamics, Inc., (“AND”) and Fox Chase Chemical Diversity Center, Inc., on December 18, 2020

HitGen Inc. is pleased to announce that HitGen and Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada, expand their collaboration with a license to develop a novel class of drugs for an early target of high interest.

BLAZE-2 Study of bamlanivimab in COVID-19 is currently underway, among residents and staff of skilled nursing or assisted living facilities

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been issued Israeli patent number 241757 by the State of Israel Patent Office titled: “TREATMENT OF PROTEIN AGGREGATION MYOPA

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced the opening of a new LuViva Reference and Training Center (“Center of Excellence”) in Budapest, Hungary to support sales and training in Europe. The

ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS Ⓡ ), today announced it has renewed its collaboration agreement with the GE Healthcare unit of General Electric Company, extending the agreements term by two years to December 16, 2023.